This medication is commonly used across conditions presenting with acute episodes of vascular head pain. It is relevant for easing challenging symptomatic manifestations, including severe migraine headaches and certain forms of cluster headaches.

---

Easing Severe, Acute Symptom Clusters

Maica is applied across domains where additional symptomatic support is needed for symptoms related to heightened physiological activity, primarily the symptoms related to physical discomfort often associated with a migraine attack. It is applied in addressing symptomatic periods when they become more noticeable, providing support that contributes to easing the overall symptom load. It is generally reserved for use in scenarios where symptoms become momentarily overwhelming and is applied in scenarios where additional management of discomfort is required.

This medicine is relevant for easing symptom clusters that may become intense or disruptive, including the pain itself alongside severe photophobia (light sensitivity) and phonophobia (sound sensitivity).

“This medicine supports patients during episodes of heightened discomfort by easing distress and helps improve day-to-day comfort during symptomatic periods.”

The available formulation options are also helpful in situations where multiple symptoms occur together, such as significant nausea and vomiting, assisting with maintaining a sense of stability when symptoms are more noticeable.

---

Quick Fact: Relief for Severe Vascular Pain and Associated Neurovascular Distress.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Map: Who can and cannot use Maica

The decision on whether a patient can receive Maica is strictly determined by governmental regulatory guidelines on population eligibility and contraindications. This information is based on the authoritative safety profile of the related medicine, Micafungin, an intravenous echinocandin antifungal.

Contraindications

• Known Hypersensitivity: Maica is formally contraindicated in patients who have a known allergy or severe hypersensitivity reaction (e.g., anaphylaxis) to the active ingredient, any component of the drug product, or other medicines belonging to the echinocandin class of antifungals.

Use in Specific Populations

• Pediatric Use: The use of Maica is established for pediatric patients four months of age and older. Safety and efficacy have not been established for infants younger than four months of age.
• Pregnancy: Based on data from animal studies, use during pregnancy is not recommended as the medication may cause potential harm to the fetus. The status is not formally prohibited but requires special consideration.
• Hepatic and Renal Impairment: No dose adjustment is required for patients with mild, moderate, or severe hepatic impairment or for patients with renal impairment. However, patients with severe hepatic or renal dysfunction should be monitored.

Interactions with other medicines and products

Maica's interaction profile is officially defined by two main regulatory constraints concerning its clearance and its pharmacological effect.

Formal Interaction Restrictions

Classification	Interacting Agents (Examples)	Constraint and Outcome
Pharmacokinetic	Strong CYP3A4 Inhibitors (e.g., Macrolide Antibiotics, HIV Protease Inhibitors, Azole Antifungals)	Contraindicated combination. Inhibition of the CYP3A4 enzyme significantly increases the plasma concentration of Ergotamine, creating a high risk of acute ergot toxicity (ergotism).
Pharmacodynamic	5-HT1 Receptor Agonists (Triptans)	Contraindicated combination. Risk of additive or synergistic vasospasm (severe blood vessel narrowing).

Mandatory Separation and Other Cautions

Co-administration with any 5-HT1 Receptor Agonist requires a mandatory separation of at least 24 hours between doses to mitigate the documented risk of vascular events. Other agents such as Beta-Blockers (e.g., Propranolol) and Sympathomimetics are officially noted to potentiate the vasoconstrictive action of the drug. A documented drug-food interaction requires that Grapefruit Juice must be avoided due to its potential interference with the CYP3A4 metabolic pathway. Furthermore, the risk of interaction-related toxicity is officially considered to be heightened in populations with Impaired Hepatic Function due to reduced clearance.

The pharmacological action of the combined product is based on modulation of vascular tone and inhibition of neurogenic signaling.

Core Mechanism: Modulation of Cranial Vascular Tone

This domain covers the direct engagement of Ergotamine Tartrate as a partial agonist at the 5- HT1 B serotonin receptors and alpha-adrenergic receptors on blood vessel walls. Activation of these targets causes the contraction of smooth muscle, initiating a cascade that leads to cranial vasoconstriction.

Inhibition of Neurogenic Signaling

This domain involves Ergotamine's binding to 5- HT1 D receptors located on presynaptic trigeminal nerve endings. This interaction suppresses the release of pro-inflammatory neuropeptides, such as CGRP, consequently suppressing the release of neuropeptides involved in inflammation and nociception.

️ Synergy Through Adenosine Antagonism

The mechanism is functionally amplified by Caffeine, which acts as an antagonist of Adenosine receptors. Since Adenosine naturally promotes vasodilation, its blockade contributes a separate layer of vasoconstriction that complements and strengthens Ergotamine's vascular mechanism, resulting in sustained changes to vascular tone.

Administration Routes and Usage Principle

Maica is administered either via the oral route as a tablet or by the rectal route using a suppository, a dual-route approach that provides a practical usage alternative when oral intake is complicated by concurrent symptoms. The medicine is exclusively designated for acute, intermittent use to address the onset of a headache and is strictly prohibited for chronic daily administration, a principle of its use.

---

Dosing Schedule and Maximum Limits

The administration pattern is structured around a precise, stepwise schedule initiated at the first sign of an acute event. For the oral tablet (containing 1 mg Ergotamine Tartrate), the initial labeled dose is 2 tablets, followed by 1 tablet every 30 minutes as needed. The maximum dosage permitted within any single attack is 6 tablets, and the total permitted use is limited to 10 tablets over a 7 -day period.

Alternatively, the rectal suppository (containing 2 mg Ergotamine Tartrate) is administered as an initial unit, with the option for a second, final suppository after 1 hour if required. The maximum labeled use for the rectal form is 2 suppositories per attack and 5 suppositories over a 7 -day period.

---

Procedural Administration Constraints

The suppository must not be cut or broken. Furthermore, the patient is instructed to remain recumbent for approximately 15 minutes following rectal administration, a procedural condition to ensure proper use.

Research evidence / Overview of Studies for Maica

Evidence for Use in Acute Migraine Headaches

Research for Maica (Ergotamine Tartrate/Caffeine) has been primarily focused on its use during the acute episode of a migraine attack in adults. The foundational evidence relies largely on Randomized Controlled Trials (RCTs), often using a cross-over design, which allows researchers to compare the study medication to an inactive substance (a placebo) in individuals experiencing symptoms. These studies were used in research exploring how symptoms change over time following administration.

The studies monitored several outcomes related to physical discomfort, including the measurement of how many people reported a change in pain state from severe to mild or none. Pharmacokinetic studies also examined how the body processes the medicine, specifically investigating the impact of the added caffeine. These studies described findings related to the absorption of the primary active ingredient.

Research on Associated Symptoms and Alternative Formulations

Maica was studied in relation to several accompanying symptoms. Studies examined outcomes related to systemic or functional imbalance commonly associated with a migraine attack, such as severe nausea and vomiting. The available research provides context for the use of the rectal suppository formulation as an alternative route of administration when oral dosing is challenging due to associated symptoms.

Evidence Gaps and Areas of Scientific Uncertainty

The research landscape contains recognized gaps. The evidence quality varies across studies, with many foundational trials considered historical. A key uncertainty is the low and variable absorption rate observed in the pharmacokinetic studies for the oral tablet, which may influence how individuals respond to the treatment. Additionally, comparative evidence is lacking—specifically, there are few modern, large-scale studies that directly compare Maica against newer first-line acute migraine medications. Research does not determine whether an individual will respond similarly outside of the core populations initially studied.

Key Studies & References

1. Migraine Treatment: Acute Treatments for Episodic Migraine
2. Ergotamine: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing

Common questions about Maica (FAQ)

Q: How quickly should I expect to feel a difference after starting Maica?

Official product information states that Maica is intended for use at the first sign of an acute headache event. Clinical studies and regulatory documents indicate that relief may begin to be felt within 30 to 60 minutes after taking the medicine. This timing reflects the medicine’s designation for acute, intermittent use.

---

Q: Does Maica have a 'generic' version available?

Yes, the primary active ingredients in Maica, Ergotamine Tartrate and Caffeine, are widely available in generic form. These generic versions are supplied by various manufacturers and are chemically equivalent to the brand name product.

---

Q: Can Maica be taken if I already take a vitamin supplement?

Regulatory documents advise patients to always inform their healthcare provider about all substances they are taking. This includes prescription and over-the-counter medicines, as well as herbal, vitamin, and mineral supplements. This disclosure assists the provider in reviewing the potential for interactions that could affect safety or efficacy.

---

Q: What happens if I forget to take a dose of Maica?

This medicine is used on an as-needed basis to address an acute attack, meaning doses are not taken on a fixed daily schedule. If a dose is not taken when needed, it is typically skipped if it is close to the time for the next potential dose. The established maximum dose limits should not be exceeded.

---

Q: Will taking Maica affect my ability to drive or operate machinery?

Official safety documents report side effects that may impair attention and coordination, such as dizziness, weakness, or tingling sensations (paresthesia). Regulatory documents indicate that caution is advised when performing tasks that require mental alertness.

---

Q: Is it normal to feel tired when you first start Maica?

Adverse event reports included in the official labeling list symptoms such as drowsiness (somnolence) and general feelings of weakness. Although these effects may not be categorized as common, they are documented side effects associated with the medicine’s use.

---

Q: Do I need to change my diet while using Maica?

Yes, official drug-food interaction documents explicitly state that Grapefruit or grapefruit juice must be avoided while using this medication. Furthermore, patients are advised to limit or reduce their intake of other products that contain additional caffeine.

---

Q: Is Maica an opioid or a controlled substance?

Maica is classified as an ergot alkaloid used as an antimigraine agent, which is its official pharmacological classification. Regulatory agencies generally do not classify this medicine as an opioid or as a controlled substance under the U.S. Controlled Substances Act (CSA).

---

Q: Can Maica be split in half?

Official usage instructions stipulate that the rectal suppository formulation must not be cut or broken before administration. While a specific general instruction for splitting the oral tablet may not be available on all labels, the tablet formulation is generally used by swallowing it whole.

---

Q: How long does Maica stay in your system after you stop taking it?

The duration the medicine remains in the body is governed by its half-life, a scientific measure that is detailed in the regulatory label’s clinical pharmacology section. However, the label does not provide a simple, specific 'time-out' period for patients to follow.

---

Q: What should I do if I experience a side effect from Maica?

Regulatory guidelines state that a healthcare provider should be contacted immediately if a patient experiences any serious or concerning side effects. Patients also have the option to report adverse events directly to government regulatory bodies through official programs like MedWatch.

---

Q: Does Maica interact with over-the-counter pain relievers like ibuprofen?

Due to the potential for drug interactions, official documents advise patients to consult with a healthcare provider before taking any over-the-counter pain relievers. The patient's healthcare provider is best positioned to assess the need for and potential impact of this combination.

---

Q: What is the risk of dependence or addiction with Maica?

Official information states that taking this medicine more often than prescribed or for long periods can lead to serious unwanted effects. This includes developing a physical dependence, which can manifest as rebound headaches if the drug is stopped.

---

Q: What does the full list of ingredients in Maica include?

Official product labeling provides a complete list of ingredients in the 'Description' section. This includes both the active ingredients (Ergotamine Tartrate and Caffeine) and the inactive ingredients used in the specific formulation, though these inactive components can vary by manufacturer.

---

Q: What is the difference between the brand name Maica and its chemical name?

The brand name (Maica) is the commercial name given by the manufacturer for the specific medicine. The chemical name, which is also listed in regulatory documents, is the scientific term that describes the exact molecular structure of the primary active ingredient, Ergotamine Tartrate.

---

Q: Is it safe to suddenly stop taking Maica?

Official warnings mention the risk of withdrawal symptoms following the discontinuation of the medicine, especially after prolonged or frequent use. The most commonly reported withdrawal symptom is the occurrence of rebound headaches. The management of cessation requires specific professional guidance.

---

Q: What happens if I miss several days of Maica doses?

This medicine is used acutely, and regulatory documents specify strict weekly maximum limits on the number of doses that can be taken. Missing several days means the original maximum limit remains in effect for the remainder of that 7-day period, and the overall limit should not be exceeded.

---

Q: Do I need a special blood test before starting Maica?

The medicine has official contraindications (reasons not to use it) related to pre-existing conditions like heart disease or impaired liver and kidney function. Official documents indicate that healthcare providers may require blood tests or other assessments to check for these specific contraindicating conditions before prescribing.

---

Q: Can Maica be taken with food, or does it need to be taken on an empty stomach?

Official instructions generally state that the oral tablet formulation of the medicine can be taken with or without food. However, patients are still required to avoid specific foods, such as grapefruit, due to interaction risks.

---

Q: Does Maica interact with herbal supplements like St. John's Wort?

Official regulatory sources warn that Maica interacts with substances that affect the CYP3A4 enzyme, which is responsible for drug metabolism. Patients are officially advised to consult a healthcare provider about all herbal supplements, as they may carry relevant interaction risks.

---

Q: Can Maica affect my mood or cause anxiety?

Adverse event reports included in the official labeling list effects on the central nervous system, such as anxiety, nervousness, and tremors (shaking). These effects are documented and are primarily attributed to the presence of the caffeine component in the combination product.

---

Q: What is the half-life of Maica?

The half-life is a specific measure of time that indicates how long it takes for the active substance concentration in the body to be reduced by half. Regulatory labels provide the half-life value for the active component, Ergotamine Tartrate, within the Clinical Pharmacology section.

Official Storage and Handling Requirements

Storage Component	Official Requirement
Temperature	Oral tablets must be stored at Controlled Room Temperature (20 C to 25 C). Rectal suppositories typically require storage in the refrigerator (2 C to 8 C).
Protection	The product must be protected from light and heat. Store away from excessive moisture and do not freeze the suppositories.
Container Rule	Keep the medicine in its original container, and the container must be kept tightly closed.
Child Safety	The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Official disposal protocols indicate that unused or expired product should be disposed of via a drug take-back program. If this is not available, the product must be removed from the container, mixed with an undesirable substance (such as used coffee grounds), and placed into a sealed bag or container before being thrown into the household trash. The medicine must not be flushed down the sink or toilet.